CX Daily: Where China Stands in the Nuclear Medicine Gold Rush
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
Novartis’s targeted radiopharmaceutical drug Pluvicto is used to treat prostate cancer. Photo: VCG
TOP STORIES
In Depth: Where China Stands in the Nuclear Medicine Gold Rush
Often tucked in out-of-the way corners of Chinese hospitals, nuclear medicine departments have for much of their history been mysterious places where few knew exactly what they do there.
What exactly they do there, though, is quickly becoming one of the more technologically promising fields of medicine and active areas of investment in the global pharmaceutical industry.
FINANCE & ECONOMY
China Approves New Asset Investment Arms for CITIC Bank, China Merchants Bank
Register to read this article for free.
Register
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
Share this article
Open WeChat and scan the QR code
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新